150 related articles for article (PubMed ID: 24968404)
1. Progressive chromogenic anti-factor Xa assay and its use in the classification of antithrombin deficiencies.
Kovács B; Bereczky Z; Selmeczi A; Gindele R; Oláh Z; Kerényi A; Boda Z; Muszbek L
Clin Chem Lab Med; 2014 Dec; 52(12):1797-806. PubMed ID: 24968404
[TBL] [Abstract][Full Text] [Related]
2. The superiority of anti-FXa assay over anti-FIIa assay in detecting heparin-binding site antithrombin deficiency.
Kovács B; Bereczky Z; Oláh Z; Gindele R; Kerényi A; Selmeczi A; Boda Z; Muszbek L
Am J Clin Pathol; 2013 Nov; 140(5):675-9. PubMed ID: 24124146
[TBL] [Abstract][Full Text] [Related]
3. Development of a novel, rapid assay for detection of heparin-binding defect antithrombin deficiencies: the heparin-antithrombin binding (HAB) ratio.
Moore GW; de Jager N; Cutler JA
Thromb Res; 2015 Jan; 135(1):161-6. PubMed ID: 25466846
[TBL] [Abstract][Full Text] [Related]
4. Antithrombin heparin binding site deficiency: A challenging diagnosis of a not so benign thrombophilia.
Orlando C; Heylen O; Lissens W; Jochmans K
Thromb Res; 2015 Jun; 135(6):1179-85. PubMed ID: 25837307
[TBL] [Abstract][Full Text] [Related]
5. Antithrombin deficiency in three Japanese families: one novel and two reported point mutations in the antithrombin gene.
Maruyama K; Morishita E; Karato M; Kadono T; Sekiya A; Goto Y; Sato T; Nomoto H; Omi W; Tsuzura S; Imai H; Asakura H; Ohtake S; Nakao S
Thromb Res; 2013 Aug; 132(2):e118-23. PubMed ID: 23809926
[TBL] [Abstract][Full Text] [Related]
6. Measurement of antithrombin activity by thrombin-based and by factor Xa-based chromogenic substrate assays.
Beeck H; Nagel D; Pindur G; Scharrer I; Preiss A; Seiler D; Hellstern P
Blood Coagul Fibrinolysis; 2000 Mar; 11(2):127-35. PubMed ID: 10759005
[TBL] [Abstract][Full Text] [Related]
7. Great discrepancy in antithrombin activity measured using five commercially available functional assays.
Javela K; Engelbarth S; Hiltunen L; Mustonen P; Puurunen M
Thromb Res; 2013 Jul; 132(1):132-7. PubMed ID: 23768451
[TBL] [Abstract][Full Text] [Related]
8. Homozygous or compound heterozygous qualitative antithrombin III deficiency.
Cucuianu M; Blaga S; Pop S; Olinic D; Olinic N; Colhon D; Cristea A
Nouv Rev Fr Hematol (1978); 1994 Aug; 36(4):335-7. PubMed ID: 7971256
[TBL] [Abstract][Full Text] [Related]
9. An antithrombin III assay based on factor Xa inhibition provides a more reliable test to identify congenital antithrombin III deficiency than an assay based on thrombin inhibition.
Demers C; Henderson P; Blajchman MA; Wells MJ; Mitchell L; Johnston M; Ofosu FA; Fernandez-Rachubinski F; Andrew M; Hirsh J
Thromb Haemost; 1993 Mar; 69(3):231-5. PubMed ID: 8470046
[TBL] [Abstract][Full Text] [Related]
10. Laboratory diagnosis of hereditary thrombophilia.
Michiels JJ; Hamulyák K
Semin Thromb Hemost; 1998; 24(4):309-20. PubMed ID: 9763348
[TBL] [Abstract][Full Text] [Related]
11. Activated Factor X-Based versus Thrombin-Based Antithrombin Testing in Thrombophilia Workup in the DOAC Era.
Rühl H; Reda S; Müller J; Oldenburg J; Pötzsch B
Thromb Haemost; 2018 Feb; 118(2):381-387. PubMed ID: 29378360
[TBL] [Abstract][Full Text] [Related]
12. The Homozygous Type II Antithrombin Deficient Pregnant Woman Monitored by Thrombin Generation Assay.
Malikova I; Husakova M; Bilkova J; Brzezkova R; Hrachovinova I; Kvasnicka T
Clin Lab; 2023 Oct; 69(10):. PubMed ID: 37844053
[TBL] [Abstract][Full Text] [Related]
13. Homozygous variant of antithrombin III that lacks affinity for heparin, AT III Kumamoto.
Okajima K; Ueyama H; Hashimoto Y; Sasaki Y; Matsumoto K; Okabe H; Inoue M; Araki S; Takatsuki K
Thromb Haemost; 1989 Feb; 61(1):20-4. PubMed ID: 2749590
[TBL] [Abstract][Full Text] [Related]
14. Inherited antithrombin deficiency: a review.
Patnaik MM; Moll S
Haemophilia; 2008 Nov; 14(6):1229-39. PubMed ID: 19141163
[TBL] [Abstract][Full Text] [Related]
15. Antithrombin III deficiency.
Cucuianu M; Blaga S; Pop S; Olinic D; Olinic N; Colhon D; Cristea A
Rom J Intern Med; 1994; 32(2):119-27. PubMed ID: 7920326
[TBL] [Abstract][Full Text] [Related]
16. Clinical multicenter evaluation of a new FXa-based Antithrombin assay.
Merz M; Böhm-Weigert M; Braun S; Cooper PC; Fischer R; Hickey K; Steffan A; Kemkes-Matthes B; Kitchen S
Int J Lab Hematol; 2011 Oct; 33(5):498-506. PubMed ID: 21535419
[TBL] [Abstract][Full Text] [Related]
17. Revisiting antithrombin in health and disease, congenital deficiencies and genetic variants, and laboratory studies on α and β forms.
Amiral J; Seghatchian J
Transfus Apher Sci; 2018 Apr; 57(2):291-297. PubMed ID: 29784539
[TBL] [Abstract][Full Text] [Related]
18. Antithrombin.
Hepner M; Karlaftis V
Methods Mol Biol; 2013; 992():355-64. PubMed ID: 23546728
[TBL] [Abstract][Full Text] [Related]
19. Thrombin-based antithrombin assays show overestimation of antithrombin III activity in patients on heparin therapy due to heparin cofactor II influence.
Bohner J; von Pape KW; Blaurock M
Thromb Haemost; 1994 Mar; 71(3):280-3. PubMed ID: 8029789
[TBL] [Abstract][Full Text] [Related]
20. Comparison of the anticoagulant response of a novel fluorogenic anti-FXa assay with two commercial anti-FXa chromogenic assays.
Harris LF; O'Brien A; Castro-López V; O'Donnell JS; Killard AJ
Thromb Res; 2011 Dec; 128(6):e166-70. PubMed ID: 21872908
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
